I'rom Group

I'rom Group, established in 1997, is a specialized entity operating within advanced medical fields, focusing on regenerative medicine and gene drug development. The company is instrumental in the commercialization of clinical IPS cell production tools, alongside the development of novel treatments for conditions such as ischemic limbs and vaccines for infectious diseases, including AIDS. Their overarching mission is to foster a future characterized by hope, safety, and comprehensive health for all individuals globally. This commitment drives their innovation in critical healthcare sectors.

The organization structures its operations across four primary business areas: advanced medical treatment, site management organization (SMO), contract research organization (CRO), and dedicated medical support services. With a workforce comprising 500 - 1,000 employees, I'rom Group maintains a significant operational footprint. For insights into the individuals driving these initiatives, one can Meet I'rom Group's team. The company's revenue reached $109.1M, reflecting its substantial market presence and operational scale within the business services sector.

Operating under the ticker (empty), I'rom Group leverages its expertise in the business services industry. Its strategic focus on cutting-edge medical technologies and services positions it as a key player. The company's fiscal year concludes on March 31st, as indicated by its hashtags. While specific location details are limited to one primary site, the company's impact is felt through its specialized offerings in regenerative medicine and drug development, contributing to advancements in patient care and disease prevention.